Fibrogenesis in nonalcoholic steatohepatitis

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 2, 2011, Pages 179-187

  De Minicis, Samuele ^a   Svegliati Baroni, Gianluca ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

fatty liver; fibrogenic cells; fibrosis; hepatic stellate cells; nonalcoholic fatty liver diseases; nonalcoholic steatohepatitis; obesity; reactive oxygen species

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CELL NUCLEUS RECEPTOR; FATTY ACID SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESISTIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROGENESIS; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID DIET; LIPOTOXICITY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; WEIGHT REDUCTION;

ADIPOKINES; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FATTY LIVER; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; MICE; MYOFIBROBLASTS; OXIDATIVE STRESS; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 79954495248     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.11.28     Document Type: Review

References (117)

1. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221-1231 (2002).
2. Teli MR, James OF, Burt AD et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22, 1714-1719 (1995).
3. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 129, 375-378 (2005). (Pubitemid 41002070)
4. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am. J. Gastroenterol. 98, 2042-2047 (2003). (Pubitemid 37185803)
5. Powell EE, Cooksley WG, Hanson R et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11, 74-80 (1990). (Pubitemid 20075105)
6. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J. Hepatol. 40, 578-584 (2004). (Pubitemid 38367778)
7. Fassio E, Alvarez E, Dominguez N et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40, 820-826 (2004). (Pubitemid 39288114)
8. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413-1419 (1999). (Pubitemid 29258890)
9. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129, 113-121 (2005). (Pubitemid 41002048)
10. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50, 1844-1850 (2001). (Pubitemid 33641605)
11. Gastaldelli A, Cusi K, Pettiti M et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and Type 2 diabetic subjects. Gastroenterology 133, 496-506 (2007). (Pubitemid 47187337)
12. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183-1192 (2001). (Pubitemid 32246672)
13. Fabbrini E, Mohammed BS, Magkos F et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134, 424-431 (2008). (Pubitemid 351173050)
14. Leclercq IA, Farrell GC, Field J et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 105, 1067-1075 (2000). (Pubitemid 30217691)
15. Perez-Carreras M, Del Hoyo P, Martin MA et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38, 999-1007 (2003). (Pubitemid 37221683)
16. Yamaguchi K, Yang L, McCall S et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45, 1366-1374 (2007). (Pubitemid 46918320)
17. McPherson S, Stewart SF, Henderson E et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59, 1265-1269 (2010).
18. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005). (Pubitemid 40770284)
19. De Minicis S, Seki E, Uchinami H et al. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 132, 1937-1946 (2007). (Pubitemid 46677935)
20. Senoo H, Kojima N, Sato M. Vitamin A-storing cells (stellate cells). Vitam. Horm. 75, 131-159 (2007).
21. Tuchweber B, Desmouliere A, Bochaton-Piallat ML et al. Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat. Lab. Invest. 74, 265-278 (1996). (Pubitemid 26041028)
22. Desmouliere A, Darby IA, Gabbiani G. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab. Invest. 83, 1689-1707 (2003). (Pubitemid 38018532)
23. Hinz B. Formation and function of the myofibroblast during tissue repair. J. Invest. Dermatol. 127, 526-537 (2007).
24. Rajkumar VS, Howell K, Csiszar K et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res. Ther. 7, R1113-R1123 (2005).
25. Kisseleva T, Uchinami H, Feirt N et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J. Hepatol. 45, 429-438 (2006). (Pubitemid 44142115)
26. Moore BB, Kolodsick JE, Thannickal VJ et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am. J. Pathol. 166, 675-684 (2005). (Pubitemid 40315625)
27. Piryaei A, Valojerdi MR, Shahsavani M et al. Differentiation of bone marrow-derived mesenchymal stem cells into hepatocyte-like cells on nanofibers and their transplantation into a carbon tetrachloride-induced liver fibrosis model. Stem Cell Rev. 7, 103-118 (2011).
28. Lee JM, Dedhar S, Kalluri R et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 172, 973-981 (2006).
29. Zavadil J, Bottinger EP. TGF-b and epithelial-to-mesenchymal transitions. Oncogene 24, 5764-5774 (2005).
30. Svegliati-Baroni G, Faraci G, Fabris L et al. Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut 60(1), 108-115 (2010).
31. Baroni GS, D'Ambrosio L, Curto P et al. Interferon g decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 23, 1189-1199 (1996). (Pubitemid 26137066)
32. Baroni GS, Pastorelli A, Manzin A et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver 19, 212-219 (1999). (Pubitemid 29261588)
33. Marra F, Arrighi MC, Fazi M et al. Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology 30, 951-958 (1999). (Pubitemid 29458284)
34. Milani S, Herbst H, Schuppan D et al. Cellular localization of type I III and IV procollagen gene transcripts in normal and fibrotic human liver. Am. J. Pathol. 137, 59-70 (1990). (Pubitemid 20229589)
35. Svegliati-Baroni G, Saccomanno S, van Goor H et al. Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver 21, 1-12 (2001). (Pubitemid 32112013)
36. Gabele E, Brenner DA, Rippe RA. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front. Biosci. 8, d69-d77 (2003). (Pubitemid 39069964)
37. Kaimori A, Potter J, Kaimori JY et al. Transforming growth factor-b1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J. Biol. Chem. 282, 22089-22101 (2007). (Pubitemid 47195788)
38. Nitta T, Kim JS, Mohuczy D et al. Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology 48, 909-919 (2008).
39. Zeisberg M, Yang C, Martino M et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J. Biol. Chem. 282, 23337-23347 (2007). (Pubitemid 47311952)
40. Taura K, Miura K, Iwaisako K et al. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 51, 1027-1036 (2010).
41. Omenetti A, Porrello A, Jung Y et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J. Clin. Invest. 118, 3331-3342 (2008).
42. Rygiel KA, Robertson H, Marshall HL et al. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab. Invest. 88, 112-123 (2008). (Pubitemid 351161272)
43. Xia JL, Dai C, Michalopoulos GK et al. Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am. J. Pathol. 168, 1500-1512 (2006).
44. Scholten D, Osterreicher CH, Scholten A et al. Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology 139, 987-998 (2010).
45. Desmet VJ. The amazing universe of hepatic microstructure. Hepatology 50, 333-344 (2009).
46. Roskams TA, Theise ND, Balabaud C et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 39, 1739-1745 (2004). (Pubitemid 38702678)
47. Xia X, Demorrow S, Francis H et al. Cholangiocyte injury and ductopenic syndromes. Semin. Liver Dis. 27, 401-412 (2007). (Pubitemid 350071840)
48. Ogawa W, Kasuga M. Cell signaling. Fat stress and liver resistance. Science 322, 1483-1484 (2008).
49. Paradis V, Perlemuter G, Bonvoust F et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fbrosis in nonalcoholic steatohepatitis. Hepatology 34, 738-744 (2001). (Pubitemid 32927998)
50. Ota T, Takamura T, Kurita S et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132, 282-293 (2007). (Pubitemid 46108737)
51. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 395, 763-770 (1998). (Pubitemid 28485436)
52. Chitturi S, Farrell G, Frost L et al. Serum leptin in NASH correlates with hepatic steatosis but not fbrosis: a manifestation of lipotoxicity? Hepatology 36, 403-409 (2002). (Pubitemid 34810360)
53. Leclercq IA, Farrell GC, Schriemer R et al. Leptin is essential for the hepatic fbrogenic response to chronic liver injury J. Hepatol. 37, 206-213 (2002). (Pubitemid 34833082)
54. Zografos TA, Rigopoulou EI, Liaskos C et al. Alterations of leptin during IFN-α therapy in patients with chronic viral hepatitis. J. Hepatol. 44, 848-855 (2006).
55. Aleff S, Petrai I, Bertolani C et al. Upregulation of proinfammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42, 1339-1348 (2005). (Pubitemid 43260036)
56. Adachi T, Togashi H, Suzuki A et al. NAD(P)H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology 41, 1272-1281 (2005). (Pubitemid 40770279)
57. Bataller R, Schwabe RF, Choi YH et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fbrosis. J. Clin. Invest. 112, 1383-1394 (2003). (Pubitemid 38057692)
58. De Minicis S, Seki E, Oesterreicher C et al. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fbrotic and infammatory effects of leptin on hepatic stellate cells. Hepatology 48, 2016-2026 (2008).
59. Baskol G, Baskol M, Kocer D. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin. Biochem. 40, 776-780 (2007). (Pubitemid 46961959)
60. Gawrieh S, Opara EC, Koch TR. Oxidative stress in nonalcoholic fatty liver disease: pathogenesis and antioxidant therapies. J. Invest. Med. 52, 506-514 (2004).
61. (Pubitemid 35025794)
62. Oliveira CP, Gayotto LC, Tatai C et al. Vitamin C and vitamin E in prevention of nonalcoholic fatty liver disease (NAFLD) in choline defcient diet fed rats. Nutr. J. 2, 9 (2003).
63. Tsukamoto H, Rippe R, Niemela O et al. Roles of oxidative stress in activation of Kupffer and Ito cells in liver fbrogenesis. J. Gastroenterol. Hepatol. 10(Suppl. 1), S50-S53 (1995).
64. Vignais PV The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell Mol. Life Sci. 59, 1428-1459 (2002). (Pubitemid 35239301)
65. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99, 1497-1502 (2004). (Pubitemid 39193189)
66. Mizrahi A, Molshanski-Mor S, Weinbaum C et al. Activation of the phagocyte NADPH oxidase by Rac guanine nucleotide exchange factors in conjunction with ATP and nucleoside diphosphate kinase. J. Biol. Chem. 280, 3802-3811 (2005). (Pubitemid 40223849)
67. Wheeler MD, Kono H, Yin M et al. The role of Kupffer cell oxidant production in early ethanol-induced liver disease. Free Radic. Biol. Med. 31, 1544-1549 (2001). (Pubitemid 34026339)
68. De Minicis S, Brenner DA. NOX in liver fbrosis. Arch. Biochem. Biophys. 462, 266-272 (2007).
69. Reinehr R, Becker S, Eberle A et al. Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis. J. Biol. Chem. 280, 27179-27194 (2005). (Pubitemid 41040757)
70. Bataller R, Sancho-Bru P, Gines P et al. Liver fbrogenesis: a new role for the renin-angiotensin system. Antioxid. Redox Signal. 7, 1346-1355 (2005). (Pubitemid 41232532)
71. De Minicis S, Bataller R, Brenner DA. NADPH oxidase in the liver: defensive, offensive, or fbrogenic? Gastroenterology 131, 272-275 (2006).
72. De Minicis S, Seki E, Paik YH et al. Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fbrosis. Hepatology 52, 1420-1430 (2010).
73. Arteel GE. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology 124, 778-790 (2003). (Pubitemid 36268494)
74. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112 (2006).
75. Moon KH, Hood BL, Kim BJ et al. Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats. Hepatology 44, 1218-1230 (2006). (Pubitemid 44748372)
76. Parola M, Robino G. Oxidative stress-related molecules and liver fbrosis. J. Hepatol. 35, 297-306 (2001). (Pubitemid 32803489)
77. Pietrangelo A. Iron, oxidative stress and liver fbrogenesis. J. Hepatol. 28(Suppl. 1), 8-13 (1998).
78. 4-induced fbrogenesis. Mol. Cells 10, 289-300 (2000).
79. Svegliati Baroni G, DAmbrosio L, Ferretti G et al. Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology 27, 720-726 (1998). (Pubitemid 28103548)
80. Hornyak SC, Gehlsen KR, Haaparanta T Histamine dihydrochloride protects against early alcohol-induced liver injury in a rat model. Infammation 27, 317-327 (2003). (Pubitemid 37290020)
81. Reinehr R, Haussinger D. CD95 activation in the liver: ion fuxes and oxidative signaling. Arch. Biochem. Biophys. 462, 124-131 (2007). (Pubitemid 46856315)
82. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin. Liver Dis. 28, 360-369 (2008).
83. Malhi H, Bronk SF, Werneburg NW et al. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem. 281, 12093-12101 (2006). (Pubitemid 43855473)
84. Berson A, De Beco V, Letteron P et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114, 764-774 (1998). (Pubitemid 28160411)
85. Weltman MD, Farrell GC, Hall P et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27, 128-133 (1998). (Pubitemid 28041545)
86. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 344, 721-724 (1994).
87. Seki S, Kitada T, Yamada T et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 37, 56-62 (2002). (Pubitemid 34713055)
88. Bugianesi E, Moscatiello S, Ciaravella MF et al. Insulin resistance in nonalcoholic fatty liver disease. Curr. Pharm. Des. 16, 1941-1951 (2010).
89. Singh R, Wang Y, Schattenberg JM et al. Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun overactivation. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G907-G917 (2009).
90. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511 (2004). (Pubitemid 38931765)
91. Seki E, Tsutsui H, Tsuji NM et al. Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice. J. Immunol. 169, 3863-3868 (2002).
92. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 130, 1886-1900 (2006). (Pubitemid 43668871)
93. Seki E, Tsutsui H, Iimuro Y et al. Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration. Hepatology 41, 443-450 (2005). (Pubitemid 40289490)
94. Senn JJ. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J. Biol. Chem. 281, 26865-26875 (2006). (Pubitemid 44401715)
95. Lee JY, Sohn KH, Rhee SH et al. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 276, 16683-16689 (2001).
96. Szabo G, Velayudham A, Romics L Jr. et al. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of Toll-like receptors 2 and 4. Alcohol Clin. Exp. Res. 29, 140S-145S (2005). (Pubitemid 43194341)
97. Seki E, De Minicis S, Osterreicher CH et al. TLR4 enhances TGF-b signaling and hepatic fibrosis. Nat. Med. 13, 1324-1332 (2007). (Pubitemid 350073596)
98. Haughton EL, Tucker SJ, Marek CJ et al. Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro. Gastroenterology 131, 194-209 (2006). (Pubitemid 44015746)
99. Wright MC. The impact of pregnane X receptor activation on liver fibrosis. Biochem. Soc. Trans. 34, 1119-1123 (2006). (Pubitemid 46769001)
100. Marek CJ, Tucker SJ, Konstantinou DK et al. Pregnenolone-16a-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms. Biochem. J. 387, 601-608 (2005). (Pubitemid 40685693)
101. Michalik L, Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J. Clin. Invest. 116, 598-606 (2006). (Pubitemid 43326864)
102. Svegliati-Baroni G, Candelaresi C, Saccomanno S et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-a and n-3 polyunsaturated fatty acid treatment on liver injury. Am. J. Pathol. 169, 846-860 (2006). (Pubitemid 44411952)
103. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 28, 551-558 (2007). (Pubitemid 350101420)
104. Galli A, Crabb DW, Ceni E et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122, 1924-1940 (2002). (Pubitemid 34651436)
105. Marra F, DeFranco R, Robino G et al. Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J. Gastroenterol. 11, 4931-4938 (2005). (Pubitemid 41227188)
106. Marra F, Efsen E, Romanelli RG et al. Ligands of peroxisome proliferator-activated receptor g modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119, 466-478 (2000). (Pubitemid 30621997)
107. Baskin-Bey ES, Huang W, Ishimura N et al. Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. Hepatology 44, 252-262 (2006). (Pubitemid 44049157)
108. Gao J, He J, Zhai Y et al. The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J. Biol. Chem. 284, 25984-25992 (2009).
109. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675-1685 (2010).
110. Li T, Owsley E, Matozel M et al. Transgenic expression of cholesterol 7a-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 52, 678-690 (2010).
111. Ma X, Hua J, Mohamood AR et al. A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology 46, 1519-1529 (2007). (Pubitemid 350155534)
112. Diehl AM. Lessons from animal models of NASH. Hepatol. Res. 33, 138-144 (2005). (Pubitemid 41799792)
113. Sahai A, Malladi P, Pan X et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am. Physiol. Gastrointest. Liver Physiol. 287, G1035-G1043 (2004). (Pubitemid 39423696)
114. Witek RP, Stone WC, Karaca FG et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 50, 1421-1430 (2009).
115. Shimada M, Hashimoto E, Taniai M et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 37, 154-160 (2002). (Pubitemid 34713069)
116. Kitamura K, Tada S, Nakamoto N et al. Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis. J Gastroenterol. Hepatol. 22, 2022-2033 (2007). (Pubitemid 47525076)
117. Wang B, Majumder S, Nuovo G et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 50, 1152-1161 (2009).